Refine by
Parkinson S Disease Articles & Analysis
108 news found
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
BlueRock, a pioneer in stem cell engineered cell therapy, is advancing a growing pipeline of innovative therapies for treating patients with neurological, immunological, cardiovascular and ophthalmic diseases. Its most advanced program BRT-DA01 is being developed for the treatment of Parkinson’s disease, a progressive ...
ByBayer AG
“The collaboration pairs AskBio’s expertise in synthetic DNA and CRISPR applications with ReCode’s novel SORT LNP delivery technology to potentially discover new genetic medicines,” said AskBio’s Chief Executive Officer Sheila Mikhail. ...
ByBayer AG
ADHD market. Cingulate’s approach is designed to provide entire active-day efficacy and a fast onset of action in a single tablet with the potential for improved tolerability. Additionally, Cingulate’s approach aims to reduce patient cost by offering eight dose strengths that medical professionals can use to optimize a patient’s ...
Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, and device technology, the company’s mission is to pave the way in treating complex CNS disorders, including Alzheimer’s disease, cognitive aging, Lewy body dementia, Parkinson’s ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. ...
Over the past 90 days, the Company has been focused on the optimization of its Rotigotine TDS formulation for the treatment of Parkinson’s disease, with multiple novel but related formulas under development. ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s ...
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
“Exosomes are a rapidly growing research area for biomarker discovery and the diagnosis and treatment of cancer and other diseases.” “There are different purposes for INOVIQ’s diagnostic products, from screening to detect disease earlier in asymptomatic people, through to diagnosis of disease and then ...
But since no procedure is without risk, let’s understand each. What is Local Anesthesia? Local is a route of administration of a drug. ...
The procedure was performed in the angiography suite with a minimally invasive, endovascular approach. Mount Sinai’s Department of Rehabilitation and Human Performance helped coordinate the procedure. The procedure marks the first U.S. patient implant in Synchron’s COMMAND trial, which is being conducted under the first investigational device ...
“Kurt joins us at a crucial moment in our development, on the heels of successful clinical results in our Australia trial, and commencement of our U.S. trial.” Haggstrom’s hiring follows Synchron’s recent enrollment of the first-ever BCI implant in the U.S. at Mount Sinai hospital in New York. ...
Wainwright BIOCONNECT Conference Date: January 10 – 13, 2022 Presentation Time: Available on-demand January 10, 2022 at 7:00 am ET Webcast: https://journey.ct.events/view/af6d1ca2-50d5-48b4-a5ce-ae85ca68054f Conference Website: Click here The presentation can also be accessed from Acorda’s website: https://ir.acorda.com/investors/investor-events/default.aspx About ...
INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.(1) Under the terms of the distribution and supply agreements, Acorda will receive a significant double-digit percent of the selling ...
Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, neuroscience, and device technology, Kurve Therapeutics is paving the way for revolutionary clinical success in treating complex CNS disorders including Alzheimer’s disease, cognitive aging, Lewy body dementia, and ...
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the publication of the 2022 Annual Letter to Shareholders published in the Company's Proxy Statement for its Annual Meeting of Stockholders that occurred on ...
The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an international network of innovators and influencers. ...
Molomics has used this approach toward advancing the treatment of Parkinson's Disease to develop a drug that addresses Levadopa Induced Dyskinesia, a movement disorder that affects Parkinson patients. Molomics’ technology will seamlessly integrate into VeriSIM’s 'virtual drug development engine', BIOiSIM™, to ...